A Study to Analyze NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma

Overview

About this study

The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with temozolomide (TMZ) in patients with diffuse gliomas at first relapse (Phase I),  and to determine the antitumor effectiveness of the combination of NMS-03305293 and TMZ in patients with isocitrate dehydrogenase (IDH) wild type glioblastoma at first relapse as measured by the 6-month Progression Free Survival (PFS) rate (Phase II).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Phase I (except for Glioblastoma Expansion Cohort)

  • Histologically confirmed diagnosis of an intracranial diffuse glioma (i.e., diffuse astrocytoma, oligodendroglioma or glioblastoma).
  • Patients at first relapse after chemotherapy including temozolomide as long as no more than 12 cycles of temozolomide were administered.

Phase II and Phase I Glioblastoma Expansion Cohort

  • Histologically confirmed diagnosis of IDH wild type glioblastoma as per WHO 2016 classification or c-IMPACT-NOW 3 definition including diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO Grade 4. IDH1 status must be assessed locally by immunohistochemistry (IHC). If IHC is performed and is negative, and patient is < 55 years old, sequencing or a PCR-based validated test must be performed to exclude other IDH1 or IDH2 most frequent mutations.
  • Patients at first relapse after initial standard therapy including temozolomide as long as no more than 6 cycles of temozolomide were administered and provided that patient completed standard of care concurrent temozolomide and the radiation therapy. 

Phase I and Phase II

  • Patients may have been operated for recurrence. If operated:
    • Residual and measurable disease after surgery is not required but pathology must have confirmed tumor recurrence;
    • A post-surgery MRI should be available within 48 hours following surgery;
    • Surgery completed at least 2 weeks before enrolment/randomization and patient should have fully recovered.
  • For non-operated patients, recurrent disease must be defined by at least one bidimensionally measurable contrast-enhancing lesion with clearly defined margins with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on MRI scan done within two weeks prior to enrolment/randomization.
  • Patients on steroids should have stable or decreasing dose of steroids for 7 days prior to the baseline MRI scan.
  • Life expectancy of at least 3 months.
  • Able to undergo brain MRI scans with IV gadolinium.
  • No evidence of symptomatic and acute intratumoral hemorrhage on MRI. Patients with MRI demonstrating old hemorrhage or subacute blood after a neurosurgical procedure (biopsy or resection) are eligible.
  • Sufficient tissue representative of the disease available for central MGMT promoter methylation status (Phase I and II) and IDH status evaluation (Phase I).
  • Male or female patients with age ≥ 18 years.
  • ECOG performance status 0,1, or 2.
  • Signed and dated IEC or IRB-approved Informed Consent.
  • Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to NCI CTCAE (Version 5.0) Grade ≤ 1 or to the baseline laboratory values:
    • Absolute Neutrophils Count (ANC) ≥ 1,500/mm^3 (≥ 1.5 × 10^9 /L);
    • Platelets (PLT) ≥ 100,000/mm^3 (≥ 100 × 10^9 /L);
    • Hemoglobin > 9.0 g/dL;
    • Serum Creatinine ≤ 1.5 × ULN Or Creatinine Clearance > 60 mL/min;
    • Total Serum Bilirubin ≤ 1.5 × ULN unless abnormality considered due to Gilbert’s syndrome;
    • Liver Transaminases (AST/ALT) ≤ 2.5 × ULN; ≤ 5 × ULN if liver metastases are present;
    • Alkaline Phosphatase (ALP) ≤ 2.5 × ULN; (in the absence of liver and/or bone metastases).
  • Pregnancy test if female with reproductive potential Negative within 7 days of starting treatment.
  • Patients must use effective contraception or abstinence. Female patients of childbearing potential must agree to use effective contraception or abstinence during the period of therapy and in the following 6 months after discontinuation of study treatment. Male patients must be surgically sterile or must agree to use effective contraception or abstinence during the period of therapy and in the following 6 months after discontinuation of study treatment.
  • Ability to swallow capsules intact (without chewing, crushing, or opening).
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.

Exclusion Criteria:

  • Current enrollment in another interventional clinical trial.
  • Current treatment with other anticancer agents, or treatment at recurrence with carmustine wafer implants and proteasome inhibitors.
  • Previous treatment with PCV (procarbazine, lomustine and vincristine) or any of its components, carmustine wafer implants, or bevacizumab.
  • Previous treatment with PARP inhibitors.
  • Major surgery, other than surgery for recurrent diffuse glioma, within 4 weeks prior to treatment.
  • Standard radiotherapy within the three months (12 weeks) prior to the diagnosis of progression unless the progression is clearly outside the radiation field (e.g., beyond the high-dose region or 80% isodose line) or unless the recurrence is histologically proven.
  • Prior radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy, unless the recurrence is histologically proven.
  • Use of full-dose anticoagulants unless the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks before enrollment (Phase I) or randomization (Phase II).
  • Treatment with concomitant medications known to be sensitive substrates of CYP2D6 and CYP2C19 that cannot be replaced with another treatment.
  • Treatment with enzyme-inducing anti-epileptic drugs (EIAED). Patients may be on non-EIAED or not be taking any anti-epileptic drugs. Patients previously on EIAED must be fully switched to non-EIAED at least 2 weeks prior to enrolment/randomization.
  • Pregnant or breast-feeding women.
  • Known hypersensitivity to any component of NMS-03305293 or TMZ (Phase I, Phase II) or lomustine (Phase II) drug formulations.
  • Known active infections (bacterial, fungal, viral including HIV positivity) requiring systemic treatment.
  • Patients with QTc interval ≥ 480 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment should be considered. If replacement is not possible, a careful risk/benefit evaluation should be performed prior to enrollment.
  • Active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn’s disease, ulcerative colitis, or short gut syndrome) or other syndromes that would impact on drug absorption.
  • Planned vaccinations with live vaccines (Phase II).
  • Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, active bleeding disorder.
  • Prior invasive malignancy (except for non melanoma skin cancer, carcinoma in situ of the cervix or localized cancer) unless the patient has been disease-free and off therapy for that disease for ≥ 3 years.
  • History of coeliac disease and wheat allergy (Phase II).
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sani Kizilbash, M.D., M.P.H.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20516465

Mayo Clinic Footer